

Efavirenz/Lamivudine/Tenofovir
Disoproxil Fumarate
600 mg/300 mg/300 mg Tablets
(Macleods Pharmaceuticals Ltd), HA611

WHOPAR part 8

Updated: October 2019

Steps taken following Prequalification of Efavirenz/Lamivudine/Tenofovir disoproxil fumarate 600 mg/300 mg/300mg Tablets* :

Changes	WHOPAR parts affected	Accepted on
Change in the FPP primary packaging pack	3, 4	12 October 2016
Addition of debossing on tablets	3, 4	08 July 2019

*Trade names are not prequalified by WHO. This is the national medicines regulatory authority's (NMRA) responsibility. Throughout this WHOPAR the proprietary name is given as an example only.